COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device

Summary

A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.

Eligibility

Inclusion Criteria:

* adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.

  * Written informed consent from patient or if not possible due to encephalopathy (\> grade 2): legal representative
  * acute-on-chronic liver failure (ACLF) grade ≥ 2:

    * Acute decompensation event (identifiable trigger)
    * Hepatic encephalopathy grade ≥ 2
    * Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg/dl OR urine output ≤ 0.3 ml/kg/h for ≥ 24 hours OR anuria for ≥ 12 hours)
    * Serum bilirubin ≥ 10 mg/dl
    * Hemodynamic instability with vasopressor support (norepinephrine \> 0.05 mcg/kg/min)

Exclusion Criteria:

* • known patient will against participation in the study or against the measures applied in the study

  * a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours
  * no complete remission of malignancy including hepatocellular carcinoma within the past 12 months
  * ongoing intermittent or CRRT before study inclusion

Conditions5

Browse More Trials